Zobrazeno 1 - 10
of 89
pro vyhledávání: '"Shinichiro Suzuki"'
Autor:
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, Kazuhiko Nakagawa
Publikováno v:
Esophagus. 20:281-289
Neoadjuvant docetaxel plus cisplatin and 5-FU (NAC-DCF) and adjuvant nivolumab monotherapy are the standard care for locally advanced resectable esophageal squamous cell carcinoma (ESCC). However, no effective biomarkers have been found in perioperat
Autor:
Kazuhiko Nakagawa, Kazuto Nishio, Kazuko Sakai, Hidetoshi Hayashi, Hisato Kawakami, Junko Tanizaki, Koji Haratani, Hitomi Sakai, Ryoji Kato, Toshiyuki Takehara, Takeshi Teramura, Kimio Yonesaka, Shinichiro Suzuki
Purpose:Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::515508c588c2e1caeb4109c863e2de8b
https://doi.org/10.1158/1078-0432.c.6530453.v1
https://doi.org/10.1158/1078-0432.c.6530453.v1
Autor:
Toshiyuki Takehara, Kimio Yonesaka, Hitomi Sakai, Koji Haratani, Hidetoshi Hayashi, Kazuko Sakai, Hisato Kawakami, Kazuhiko Nakagawa, Takeshi Teramura, Shinichiro Suzuki, Kazuto Nishio, Ryoji Kato, Junko Tanizaki
Publikováno v:
Clinical Cancer Research. 27:5697-5707
Purpose: Treatment with KRASG12C inhibitors such as sotorasib can produce substantial regression of tumors in some patients with non–small cell lung cancer (NSCLC). These patients require alternative treatment after acquiring resistance to the inhi
Autor:
Masayuki Takeda, Kazuto Nishio, Takayuki Takahama, Hidetoshi Hayashi, Kazuko Sakai, Takeshi Yoshida, Kazuhiko Nakagawa, Shinichiro Suzuki, Hiroyasu Kaneda, Kaoru Tanaka, Ryoji Kato, Koji Haratani, Yoshikane Nonagase, Junko Tanizaki, Kimio Yonesaka
Publikováno v:
International Journal of Clinical Oncology. 26:1628-1639
We here applied cancer personalized profiling by deep sequencing (CAPP-seq) to analysis of circulating tumor DNA (ctDNA) to identify resistance mechanisms in osimertinib-treated patients with EGFR T790M–positive non–small cell lung cancer (NSCLC)
Autor:
Hiroaki Kanemura, Hidetoshi Hayashi, Shuta Tomida, Junko Tanizaki, Shinichiro Suzuki, Yusuke Kawanaka, Asuka Tsuya, Yasushi Fukuda, Hiroyasu Kaneda, Keita Kudo, Takayuki Takahama, Ryosuke Imai, Koji Haratani, Yasutaka Chiba, Tomoyuki Otani, Akihiko Ito, Kazuko Sakai, Kazuto Nishio, Kazuhiko Nakagawa
Publikováno v:
JTO clinical and research reports. 3(8)
Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients.A total of 135 p
Autor:
Shinichiro Suzuki, Kazuya Fukuoka, Hisato Kawakami, Soichi Fumita, Kazuhiko Nakagawa, Hidetoshi Hayashi, Chihiro Sato, Kazuko Sakai, Shigeki Shimizu, Tatsuya Okuno, Koji Haratani, Akihiko Ito, Yoshikane Nonagase, Kazumasa Saigoh, Kimio Yonesaka, Hisashi Handa, Takeshi Yoshida, Masayuki Takeda, Tetsuya Mitsudomi, Kazuto Nishio, Takayuki Takahama, Naoki Takegawa, Satomi Watanabe, Kaoru Tanaka
Publikováno v:
The Oncologist
Background Implementation of personalized medicine requires the accessibility of tumor molecular profiling in order to allow prioritization of appropriate targeted therapies for individual patients. Our aim was to study the role of comprehensive geno
Autor:
Seiichiro Mitani, Hisato Kawakami, Osamu Shiraishi, Hiroaki Kanemura, Shinichiro Suzuki, Koji Haratani, Hidetoshi Hayashi, Kimio Yonesaka, Yasutaka Chiba, Takushi Yasuda, Kazuhiko Nakagawa
Publikováno v:
Esophagus. 20:290-290
Autor:
Kazuhiko Nakagawa, Seiichiro Mitani, Shinichiro Suzuki, Takashi Kurosaki, Yasumasa Nishimura, Hidetoshi Hayashi, Soichi Fumita, Naoki Otsuki, Kazuki Ishikawa, Takeshi Yoshida, Katsumi Doi, Hiroaki Kanemura, Koji Haratani, Kaoru Tanaka, Mutsukazu Kitano, Tsutomu Iwasa
Publikováno v:
Anti-Cancer Drugs
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) in front-line use; however, subsequent systemic therapy has not been optimized. This study aimed to evaluate the safety a
Publikováno v:
Scientific Reports. 12
Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their antipyretic, analgesic, and anti-inflammatory properties. However, various aspects of NSAID-induced lower gastrointestinal tract injury remain unclear, and effective prophylaxis
Autor:
Shinichiro, Suzuki, Kimio, Yonesaka, Takeshi, Teramura, Toshiyuki, Takehara, Ryoji, Kato, Hitomi, Sakai, Koji, Haratani, Junko, Tanizaki, Hisato, Kawakami, Hidetoshi, Hayashi, Kazuko, Sakai, Kazuto, Nishio, Kazuhiko, Nakagawa
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 28(2)